• Burmese
Saturday, July 12, 2025
No Result
View All Result
NEWSLETTER
The Irrawaddy
25 °c
Yangon
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Business
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Junta Watch
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Books
  • Donation
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Business
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Junta Watch
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Books
  • Donation
No Result
View All Result
The Irrawaddy
No Result
View All Result
Home News Asia

Philippines Defied Experts’ Advice on Dengue Immunization Program

Reuters by Reuters
December 11, 2017
in Asia
Reading Time: 5 mins read
0 0
A A
A demonstrator uses a mock syringe, which features the phrase “3.5 billion pesos Dengvaxia fund investigate,” to point to a picture of President Rodrigo Duterte during a protest in front of the Philippine Department of Health in metro Manila, Philippines, on Dec. 5, 2017. / Reuters

A demonstrator uses a mock syringe, which features the phrase “3.5 billion pesos Dengvaxia fund investigate,” to point to a picture of President Rodrigo Duterte during a protest in front of the Philippine Department of Health in metro Manila, Philippines, on Dec. 5, 2017. / Reuters

5.3k
VIEWS
Share on FacebookShare on Twitter

MANILA — As she announced in January 2016 that the Philippines would immunize 1 million children with a new dengue vaccine, the nation’s then health secretary Janette Garin boasted it was a world-first and a tribute to her country’s “expertise” in research.

At the time, it seemed the Philippines could be on the cusp of a breakthrough to combat a potentially lethal tropical virus that had been endemic in large parts of the Southeast Asian nation for decades.

Almost two years later, the program lies in tatters and has been suspended after Sanofi Pasteur, a division of French drug firm Sanofi, said at the end of last month the vaccine itself may in some cases increase the risk of severe dengue in recipients not previously infected by the virus.

RelatedPosts

Mekong River Body Detects Heavy Metal Contamination

Mekong River Body Detects Heavy Metal Contamination

July 7, 2025
581
Toxic Thailand Rivers Pinned on Myanmar Mines

Toxic Thailand Rivers Pinned on Myanmar Mines

June 11, 2025
779
From Smog to Arsenic: Myanmar’s Toxic Trail Reaches Thailand

From Smog to Arsenic: Myanmar’s Toxic Trail Reaches Thailand

April 25, 2025
1.6k

Documents reviewed by Reuters that have not been disclosed until now, as well as interviews with local experts, show that key recommendations made by a Philippines Department of Health (DOH) advisory body of doctors and pharmacologists were not heeded before the program was rolled out to 830,000 children.

After Garin’s announcement, the Formulary Executive Council (FEC) of advisers urged caution over the vaccine because it said its safety and cost-effectiveness had not been established.

After twice meeting in January, the panel approved the state’s purchase of the vaccine on Feb. 1, 2016, but recommended stringent conditions, minutes of all three meetings show.

“Based on the available scientific evidence presented to the council, there is still a need to establish long-term safety, effectiveness and cost-effectiveness,” the FEC told Garin in a letter on that day. The letter was reviewed by Reuters.

The FEC said Dengvaxia should be introduced through small-scale pilot tests and phased implementation rather than across three regions in the country at the same time, and only after a detailed “baseline” study of the prevalence and strains of dengue in the targeted area, the FEC letter and minutes of the meetings said.

The experts also recommended that Dengvaxia be bought in small batches so the price could be negotiated down. An economic evaluation report commissioned by Garin’s own department had found the proposed cost of 1,000 pesos (US$21.29) per dose was “not cost-effective” from a public payer perspective, the minutes from the meetings reveal.

For reasons that Reuters was unable to determine, these recommendations were ignored.

“Very Angry”

The DOH purchased 3 million doses of Dengvaxia in one lot, enough for the required three vaccinations for each child in the proposed immunization program and paid 1,000 pesos per dose, a copy of the purchase order reviewed by Reuters shows.

It did conduct a “limited baseline study” in late February and March 2016, but the survey looked at “common illnesses” rather than the prevalence of dengue, according to guidelines issued by Garin’s office at the time and reviewed by Reuters.

Garin, who was part of the government of former president Benigno Aquino and replaced when President Rodrigo Duterte took power in June 2016, did not respond to requests for comment on why she ignored the local experts’ recommendations.

A physician, Garin has defended her conduct and a program that she said was “implemented in accordance with WHO guidance and recommendations.”

“I understand the concern,” she told Philippine TV station ABS-CBN on Friday.

“Even us, we’re also very angry when we learned about Sanofi’s announcement about severe dengue. I’m also a mother. My child was also vaccinated. I was also vaccinated.”

DOH spokesman Lyndon Lee Suy also did not respond to text messages or questions emailed to him.

Sanofi Philippines declined comment on the Philippines government decision. However, Dr. Su-Peing Ng, global medical head of Sanofi Pasteur, told Reuters: “We communicated all known benefits and risks of the vaccine to the Philippines government.”

Rontgene Solante, former president of the Philippines Society for Microbiology and Infectious Diseases, said health officials were motivated to end the debilitating impact of dengue on the Philippines, where there are about 200,000 reported cases each year and many more unreported.

Over 1,000 people died of the disease in the country last year.

Two months after the FEC wrote to the health secretary, the DOH began immunizing one million students around the age of 10 in all three target areas in April 2016, in accordance with its original plan but at odds with the FEC’s recommendations to conduct a slow roll-out of the vaccine.

“The usual process for the DOH that has protected our children for so many decades was not followed. That’s a fact,” said Susan Mercado, a former Philippines health department undersecretary and former senior official at the World Health Organization (WHO).

The WHO said in April 2016 that the Philippines’ campaign appeared to meet its criteria for using Dengvaxia because the targeted regions had high levels of dengue exposure; the vaccine would be provided to children 9 years and older; and they would each receive three doses.

The WHO was not involved in the deliberations of the FEC, according to the minutes. It said in a statement last week that a position paper on the dengue vaccine it published in July 2016 did not include a recommendation for countries to introduce it.

Now, after Sanofi’s warnings, the WHO has said it agrees with the government’s decision to suspend the immunization program.

Shouldn’t Ignore Expertise

The current secretary of health in the Duterte administration, Francisco Duque, said he would carry out a “thorough analysis” of the FEC’s recommendations and the program before passing judgment. He said the council’s recommendations were not legally enforceable.

“At the end of the day, the final decision is made by [the] secretary of health,” he told Reuters. “But because of the expertise that the members of the FEC have, it is something that you don’t want to ignore.”

Underpinning the concerns in 2016 about Dengvaxia, since confirmed by Sanofi, were fears that the vaccine would act like a primary infection for those who had never had dengue.

If they were bitten by a mosquito carrying the virus after the vaccination, it could be akin to getting dengue a second time, which often leads to far more severe symptoms and potentially death if bad cases are not treated quickly. The concerns were first raised by noted US-based tropical disease expert Dr. Scott Halstead, who urged both Sanofi and the WHO to proceed with caution.

In the Philippines, Dr. Antonio Dans, an epidemiologist from the University of the Philippines, led a delegation of physicians to the DOH in March 2016 where, citing Halstead’s research, they pressed for the campaign to be aborted.

“The data was not definitive but it was clear there were uncertainties and risks. Why not wait for the complete studies to be finished before endangering so many children?” Dans told Reuters.

In a Senate hearing late last year, Garin said she was aware of Halstead’s assessment but dismissed it. “This is a theory … it has not been proven,” she said at the time.

Fear and Confusion

Two sources involved in the program said no antibody testing was undertaken, as recommended by the FEC.

Antibody testing, while not 100 percent accurate, indicates whether an individual has had dengue before.

Duque, the current health secretary, is demanding the company refund the 3 billion pesos ($60 million) paid for the vaccinations and has threatened legal action against Sanofi if it is proven to have withheld information.

A criminal probe is underway into how a danger to public health came about and two Congressional inquiries have been convened in the Philippines.

Duque told Reuters he was concerned that the program was paid from an “off-budget” allocation, meaning it bypassed Congressional scrutiny. Reuters was unable to confirm this.

Until now, one child out of the 830,000 vaccinated, a girl who was hospitalized with severe dengue, has been linked definitively by the DOH to the campaign. But the department of health says it still does not have complete data on those who fell ill after taking Dengvaxia.

Your Thoughts …
Tags: Health
Reuters

Reuters

...

Similar Picks:

Myanmar’s Youth Flee—and They Aren’t Looking Back
Commentary

Myanmar’s Youth Flee—and They Aren’t Looking Back

by Aung Zaw
February 23, 2024
8.4k

In Thailand and farther afield, they join the wealthy and the educated who have already put down roots and invested...

Read moreDetails
Rare Earth Mining Taking Heavy Toll in Myanmar’s Kachin, Groups Say
Burma

Rare Earth Mining Taking Heavy Toll in Myanmar’s Kachin, Groups Say

by Hein Htoo Zan
May 27, 2024
5.3k

Amid heavy global demand for rare earths, local activists’ concerns about the impacts on the environment and local communities are...

Read moreDetails
Life Without Power Spells Daily Misery for Yangon’s Residents
Burma

Life Without Power Spells Daily Misery for Yangon’s Residents

by Nyein Nyein
January 29, 2025
5k

Lack of electricity affects every aspect of Yangon residents’ daily lives, from work to sleep, and now even hotter weather...

Read moreDetails
‘Everyone Sits Outside’: Parks Offer Heatwave Relief in Myanmar’s Largest City
Burma

‘Everyone Sits Outside’: Parks Offer Heatwave Relief in Myanmar’s Largest City

by AFP
April 29, 2024
4.4k

Amid searing temperatures, and without power for hours a day due to post-coup energy disruptions, Yangon residents are taking refuge...

Read moreDetails
With Motorbikes Banned, Yangon Delivery Riders Struggle in Heatwave
Burma

With Motorbikes Banned, Yangon Delivery Riders Struggle in Heatwave

by AFP
May 2, 2024
3.7k

A previous junta outlawed motorbikes for ‘security reasons’, so delivery workers rely on pedal power—a daunting prospect amid the current...

Read moreDetails
Junta Watch: New Honors to Flatter Foreign Allies; Playing the Blame Game (Again); and More
Junta Watch

Junta Watch: New Honors to Flatter Foreign Allies; Playing the Blame Game (Again); and More

by The Irrawaddy
March 23, 2024
2.7k

Also this week, the regime orchestrated Rohingya protests, lost the builder of its capital, and praised Putin after not-so-free election. 

Read moreDetails
Load More
Next Post
Rohingya refugees make their way through Kutupalong refugee camp near Cox's Bazar, Bangladesh December 10, 2017. / Reuters

International Experts Named to Rakhine Advisory Body

U Myint, March 2017. / The Irrawaddy

Stakeholders Call for Economy to be Top Priority

No Result
View All Result

Recommended

‘Reforms Are Not Optional’: Prominent Activist Urges NUG to Act Before It’s Too Late

‘Reforms Are Not Optional’: Prominent Activist Urges NUG to Act Before It’s Too Late

3 days ago
1.1k
Trump’s Tariffs to Hit Myanmar’s Garment Manufacturers Hard

Trump’s Tariffs to Hit Myanmar’s Garment Manufacturers Hard

3 days ago
1k

Most Read

  • Myanmar Junta Deploying Conscripts in Major Push to Reclaim Lost Territory

    Myanmar Junta Deploying Conscripts in Major Push to Reclaim Lost Territory

    shares
    Share 0 Tweet 0
  • Myanmar Junta Chief Thanks Trump for Shutting Down VOA and RFA

    shares
    Share 0 Tweet 0
  • Chinese Investment Reshapes Myanmar’s N. Shan as MNDAA Consolidates Power

    shares
    Share 0 Tweet 0
  • KIA Denies Rumor Chief Under House Arrest in China

    shares
    Share 0 Tweet 0
  • Anti-Coup Icon Explains Urgent Call for NUG Reform

    shares
    Share 0 Tweet 0

Newsletter

Get The Irrawaddy’s latest news, analyses and opinion pieces on Myanmar in your inbox.

Subscribe here for daily updates.

Contents

  • News
  • Politics
  • War Against the Junta
  • Myanmar’s Crisis & the World
  • Conflicts In Numbers
  • Junta Crony
  • Ethnic Issues
  • Asia
  • World
  • Business
  • Economy
  • Election 2020
  • Elections in History
  • Cartoons
  • Features
  • Opinion
  • Editorial
  • Commentary
  • Guest Column
  • Analysis
  • Letters
  • In Person
  • Interview
  • Profile
  • Dateline
  • Specials
  • Myanmar Diary
  • Women & Gender
  • Places in History
  • On This Day
  • From the Archive
  • Myanmar & COVID-19
  • Intelligence
  • Myanmar-China Watch
  • Lifestyle
  • Travel
  • Food
  • Fashion & Design
  • Videos
  • Photos
  • Photo Essay
  • Donation

About The Irrawaddy

Founded in 1993 by a group of Myanmar journalists living in exile in Thailand, The Irrawaddy is a leading source of reliable news, information, and analysis on Burma/Myanmar and the Southeast Asian region. From its inception, The Irrawaddy has been an independent news media group, unaffiliated with any political party, organization or government. We believe that media must be free and independent and we strive to preserve press freedom.

  • Copyright
  • Code of Ethics
  • Privacy Policy
  • Team
  • About Us
  • Careers
  • Contact
  • Burmese

© 2023 Irrawaddy Publishing Group. All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Home
  • News
    • Burma
    • Politics
    • World
    • Asia
    • Myanmar’s Crisis & the World
    • Ethnic Issues
    • War Against the Junta
    • Junta Cronies
    • Conflicts In Numbers
    • Junta Watch
    • Fact Check
    • Investigation
    • Myanmar-China Watch
    • Obituaries
  • Politics
  • Opinion
    • Commentary
    • Guest Column
    • Analysis
    • Editorial
    • Stories That Shaped Us
    • Letters
  • Ethnic Issues
  • War Against the Junta
  • In Person
    • Interview
    • Profile
  • Business
    • Economy
    • Business Roundup
  • Books
  • Donation

© 2023 Irrawaddy Publishing Group. All Rights Reserved

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.